

1 **Hepatitis B virus prevalence and transmission in the households of pregnant women in Kinshasa,**
2 **Democratic Republic of Congo**

3
4 Camille E. Morgan¹, Patrick Ngimbi², Alix JN Boisson-Walsh³, Sarah Ntambua², Jolie Matondo², Martine
5 Tabala², Melchior Mwandaglrwa Kashamuka⁴, Michael Emch¹, Jessie K. Edwards¹, Kimberly A. Powers¹,
6 Linda James³, Nana Mbonze², Samuel Mampunza², Marcel Yotebieng⁵, Peyton Thompson^{6*}, Jonathan B.
7 Parr^{3,7*}

8
9 ¹Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina,
10 Chapel Hill, NC, 27599, USA.

11
12 ²Université Protestante du Congo, Kinshasa, Democratic Republic of the Congo.

13
14 ³Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel
15 Hill, NC, 27599, USA.

16
17 ⁴Kinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.

18
19 ⁵Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine,
Bronx, NY, 10461, USA.

20
21 ⁶Division of Infectious Diseases, Department of Pediatrics, UNC School of Medicine, University of North
Carolina, Chapel Hill, NC 27599, USA.

22
23 ⁷Division of Infectious Diseases, Department of Medicine, UNC School of Medicine, University of North
Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.

24 * Co-senior authors.

25
26 **Keywords:** Vertical transmission, horizontal transmission, PMTCT, viral hepatitis, birth-dose vaccination

27
28 **Key points** (40/40 words)

29 HBV infection patterns in households of women receiving antenatal care in Kinshasa, DRC, suggest
30 vertical and horizontal transmission, and reveal associations with street barber use, shared nail clippers,
31 and sexual behaviors. Prevention programs must address horizontal transmission to reach elimination.

32
33 **Abstract** (CID: 239/250 words)

34
35 **Background:**

36 Despite routine infant vaccination and blood donor screening, the Democratic Republic of Congo (DRC)
37 has high hepatitis B virus (HBV) prevalence compared to the United States and Europe. Through the
38 cross-sectional Horizontal and Vertical Transmission of Hepatitis B (HOVER-HBV) study, we characterized
39 household prevalence in DRC's capital, Kinshasa, to inform additional prevention efforts.

40
41 **Methods:**

42 We introduced HBV surface antigen (HBsAg) screening alongside existing HIV screening as part of
43 routine antenatal care (ANC) in high-volume maternity clinics in Kinshasa. We recruited households of

44 pregnant women who were HBsAg-positive and HBsAg-negative, defining households as “exposed” and
45 “unexposed,” respectively. Household members underwent HBsAg testing and an epidemiological
46 survey. We evaluated HBsAg prevalence and potential transmission correlates.

47

48 **Results:**

49 We enrolled 1,006 participants from 200 households (100 exposed, 100 unexposed) across Kinshasa.
50 HBsAg prevalence was more than twice as high in exposed households (5.0%; 95% CI: 2.8%-7.1%) as in
51 unexposed households (1.9%; 0.6%-3.2%). Exposed direct offspring had 3.3 (0.9, 11.8) times the
52 prevalence of unexposed direct offspring. Factors associated with HBsAg-positivity included older age,
53 marriage, and having multiple recent partners or any new sexual partners among index mothers; and
54 older age, lower household wealth, sharing nail clippers, and using street salons among exposed
55 offspring.

56

57 **Conclusions:**

58 Vertical and horizontal HBV transmission within households is ongoing in Kinshasa. Factors associated
59 with infection reveal opportunities for HBV prevention efforts, including perinatal prevention,
60 protection during sexual contact, and sanitation of shared personal items.

61

62

63 **Word count: 2952/3000**

64

65 **Introduction**

66 Despite an effective vaccine, hepatitis B virus (HBV) infection remains highly prevalent (~6%) in Asia and
67 Africa, resulting in significant global morbidity and mortality.^{1,2} Without a therapeutic cure, infection
68 prevention remains the primary strategy to reduce HBV morbidity and mortality. However, HBV
69 vaccination alone will not achieve elimination by the 2030 target.³⁻⁵ Modeling studies indicate that test-
70 and-treat interventions can yield marked HBV prevalence reductions in Africa, but studies of prevention
71 options are hindered by the limited epidemiological data from the region.⁴ While perinatal transmission
72 is the dominant driver of ongoing endemicity in Asia,⁶⁻⁸ available studies suggest a greater contribution
73 of household and community (“horizontal”) transmission in Africa, particularly during early childhood^{9,10}
74 but also in adulthood.⁴ Improved understanding of dominant HBV transmission modes and risk factors is
75 needed to design effective interventions in Africa, especially in HBV-endemic countries like the
76 Democratic Republic of Congo (DRC).

77

78 National HBV prevalence in the DRC is estimated to be 3.3% by HBV surface antigen (HBsAg) testing,¹¹
79 translating to approximately 2.5 million chronic infections in a country where advanced hepatology care
80 is essentially inaccessible.¹² Estimated prevalence is higher among blood donors,¹³ women with HIV
81 presenting to urban antenatal care (ANC) settings,¹⁴ pregnant women in rural areas,^{15,16} healthcare
82 workers,¹⁷ and survivors of sexual violence.¹⁸ Blood donor screening and the three-dose infant
83 pentavalent vaccine series are the only HBV prevention measures implemented nationally in DRC, but
84 complete infant HBV vaccination coverage is <70%.¹⁹ For prevention of mother-to-child transmission,
85 the World Health Organization recommends ANC HBsAg screening, maternal antiviral prophylaxis, and
86 infant birth-dose vaccination to prevent perinatal transmission.²⁰ These activities are feasible in the DRC
87 but not yet implemented.^{21,22}

88

89 To investigate HBV correlates and inform expanded interventions in the DRC, we conducted the
90 Horizontal and Vertical Transmission of Hepatitis B (HOVER-HBV) study. We built upon the established
91 prevention of mother-to-child HIV transmission (PMTCT) program infrastructure to introduce ANC
92 HBsAg screening, characterize HBV prevalence in ANC patients’ households across urban Kinshasa, and
93 identify attributes and practices associated with HBsAg-positivity.

94

95 **Methods**

96

97 ***Study design and participant recruitment***

98 To recruit households, we introduced DETERMINE 2²³ (Abbott, Abbott Park, IL) point-of-care (POC)
99 HBsAg testing alongside existing ANC HIV testing in high-volume maternity centers in Kinshasa (**Figure**
100 **1**). During two recruitment periods, pregnant women screened for HBsAg were offered enrollment of
101 their households in the study. In this matriarchal design, recruited women served as “index mothers” for
102 enrolled households, with a pre-specified target of 100 households of HBsAg-positive mothers and 100
103 households of HBsAg-negative mothers.

104

105 ***Study procedures***

106 Data collection at the single household visit included POC HBsAg testing (including repeat testing of the
107 index mothers), collection of dried blood spot (DBS) specimens, and administration of household and
108 individual questionnaires (**Appendix 1**) covering demographics and potential sources of horizontal HBV
109 transmission within household and community settings. HIV infection and antiretroviral therapy (ART)
110 use, particularly tenofovir-based regimens given its anti-HBV activity, were determined by self-report. As

111 HBV can remain infectious on surfaces for at least 7 days,²⁴ we collected information about household
112 and community practices that could result in HBV transmission, based on past findings from other
113 countries in the region.^{16,25–27} We offered the three-dose Euvax-B HBV (LG Life Sciences, Republic of
114 Korea) vaccination to all HBsAg-negative individuals living with someone who was HBsAg-positive, and
115 recorded all resulting vaccinations occurring at the two centers where we offered them up to six months
116 after the last enrollment.

117

118 **Analytical approach**

119 We defined HBV-“exposed” and “unexposed” households as households of index mothers who were
120 HBsAg-positive and HBsAg-negative during ANC recruitment, respectively; in sensitivity analyses, we
121 applied alternate definitions of household exposure based on index mothers’ HBsAg status across the
122 recruitment and enrollment timepoints (**Supplementary Material**). We conducted descriptive analyses
123 of household composition, HBsAg positivity patterns within households, and household/participant
124 demographics, including composite indices of modern housing and wealth to approximate standard of
125 living across households (**Supplementary Material**). We considered participant age both continuously
126 and categorically, defining categories based on age relative to the introduction of the three-dose HBV
127 vaccination in the national infant immunization program (**Supplementary Material**).^{28,29}

128

129 In our primary analysis, we compared HBsAg prevalence between exposed and unexposed households
130 and between household member types (offspring versus other). We estimated prevalence ratios for
131 each comparison, first unadjusted and then adjusted for household clustering using a random intercept
132 for household. To examine potential correlates of HBV infection, we also estimated measures of
133 association between HBsAg positivity and individual, household, and community-level attributes and
134 practices. Variable coding is detailed in Supplementary Material. Briefly, individual attributes included
135 age and marital status; household variables included household wealth, sharing personal objects within
136 the household, and pre-masticating food for another household member; community variables included
137 receiving blood transfusions, manicures/pedicures, tattoos, traditional scarification, and a variety of
138 sexual behaviors. Given the case-control design of index mother recruitment, we used logistic
139 regression to estimate odds ratios for these factors’ associations with maternal HBsAg positivity. For the
140 analysis among household members, we conducted stratified analyses by household member type
141 (offspring vs. other household member), estimating a prevalence ratio for each attribute/practice from
142 multilevel log-binomial regression with a random intercept to account for household clustering. Where
143 log-binomial models failed to converge, we used the odds ratio from the logistic regression model to
144 approximate the prevalence ratio, which is minimally biased for rare outcomes (<10% prevalence) such
145 as HBsAg positivity.³⁰ We calculated 95% confidence intervals (CI) to assess precision of each estimate. In
146 subgroups with fewer than 10 HBsAg infections, we calculated Fisher’s exact p-values.

147

148 All data were imported into R (v4.1.1, R Core Team, Vienna, Austria) using the *REDCapR* package
149 (v1.1.0). We analyzed data using the *tidyverse* (v2.0.0), *tableone* (v0.13.2), and *lme4* (v1.1.32) packages.
150 R code is publicly available at https://github.com/IDEELResearch/hbv_hover. This study was approved
151 by the Institutional Review Board at the University of North Carolina (19-1875) and the Ethics
152 Committee at Université Protestante au Congo (CE/UPC/0062).

153

154 **Results**

155

156 **Study population**

157 From February 2021 to September 2022, we offered enrollment to 339 households, and enrolled 200
158 households and 1,006 individuals (**Figure 1**). Overall, 190 index mothers were recruited from two

159 maternity centers, and 10 women from nine other maternity centers. Participating households were
160 located in neighborhoods across metropolitan Kinshasa (**Figure 2A**). Few households (20.5%) lived in
161 modern housing structures, and most participants were transient (median of two years [IQR: 1, 5] in the
162 home) (**Table 1**). We enrolled a median of 5 (IQR: 3, 6) members per exposed and unexposed household
163 (**Figure 2B**). Most recruited index mothers were multiparous: in 176 (88%) households, we enrolled at
164 least one direct offspring, with a median of 3 children (IQR: 1,4) enrolled in both exposed and
165 unexposed households (**Table 1**). In 86 households (43%), we enrolled the index mother's sexual
166 partner, with partners enrolling in a considerably higher proportion of exposed (52%) than unexposed
167 (34%) households. Index mothers had a median age of 32 years (IQR: 27, 37), with a higher median age
168 among mothers in exposed (33 years) versus unexposed households (30 years). We enrolled 467 direct
169 offspring of index mothers (228 exposed, 239 unexposed), with similar age distributions in exposed and
170 unexposed households. Most offspring (82% exposed, 84% unexposed) were 13 years of age or younger
171 in 2022, and thus born after three-dose infant HBV vaccination was introduced in DRC. We enrolled 331
172 other household members, with the most common relationships to index mothers being
173 nieces/nephews (n=93), siblings (n=90), and partners (n=86).

174

175 ***HBsAg prevalence***

176 HBsAg prevalence among index mothers' household members was 5.0% (95% CI: 2.8%, 7.1%) and 1.9%
177 (0.6%, 3.2%) in exposed and unexposed households, respectively, corresponding to an unadjusted
178 prevalence ratio (PR) of 2.61 (1.20, 6.25), and PR adjusted for household clustering of 2.52 (0.88, 7.23)
179 (**Table 2, Supplementary Figure 3**). Overall, we observed 27 household members who were HBsAg-
180 positive (19 exposed, 8 unexposed) from 17 distinct households (**Figures 2B-2C**). We observed 15 HBsAg
181 infections among direct offspring; HBsAg prevalence among direct offspring was 5.3% (2.4%, 8.2%) in
182 exposed households and 1.3% (0.0%, 2.7%) in unexposed households, corresponding to an unadjusted
183 PR of 4.18 (1.35, 18.16) and adjusted PR of 3.33 (0.94, 11.84). Among these 15 direct offspring who were
184 HBsAg-positive, 12 had mothers who were HBsAg-positive at both timepoints; the remaining three came
185 from two households in which index mothers had incident infections. We observed 12 HBsAg infections
186 among other household members; HBsAg prevalence was 4.5% (1.2%, 7.7%) and 2.7% (0.4%, 5.1%)
187 among other household members in exposed and unexposed households, respectively, corresponding
188 to an unadjusted PR of 1.64 (95%CI: 0.53, 5.45) and adjusted PR of 1.01 (95% CI: 0.24, 4.25). We
189 observed one HBsAg infection among exposed male partners and one among unexposed male partners,
190 for a PR of 0.65 (95% CI: 0.04, 10.10) comparing those exposed to those unexposed.

191

192 In sensitivity analyses using alternate definitions of HBV exposure, household HBsAg prevalence
193 estimates were largely consistent with those obtained under the primary exposure definition
194 (Supplementary Figure 3), except for the analysis of direct offspring (all direct offspring infected lived
195 with a mother who was HBsAg-positive at least once). Of the 100 index mothers who were HBsAg-
196 positive at recruitment, 96 were HBsAg-positive and four were HBsAg-negative at enrollment (**Figure**
197 **2C**). Two women who were HBsAg-negative at recruitment were HBsAg-positive at enrollment,
198 representing incident cases of horizontal transmission, and 98 index mothers were HBsAg-negative at
199 both points.

200

201 ***Factors associated with HBsAg positivity***

202 Among index mothers, several individual attributes and potential sources of community HBV exposure
203 were associated with HBsAg positivity. Increasing age was associated with higher odds of HBsAg
204 positivity, with an odds ratio of 1.06 (1.01, 1.11) per one-year increase in age (**Figure 3, Supplementary**
205 **Figure 4**). Never having been married was associated with 0.39 (95% CI: 0.14, 0.96) times the odds of
206 HBsAg positivity compared with being married. Declining to answer age of sexual debut was associated

207 with 4.53 (95% CI: 1.81, 12.79) times the odds of HBsAg positivity compared with reporting sexual debut
208 at 18 years or older; sexual debut before 18 years was associated with higher odds of HBsAg positivity
209 compared with ≥ 18 years, but had a lower magnitude of association than declining to answer (OR: 1.21,
210 95% CI 0.66, 2.23). All variables assessing recent multiple and new sexual partners were associated with
211 higher odds of HBsAg positivity compared with the referent; for example, having at least one new sexual
212 partner in the last three months or declining to answer was associated with 3.63 (95% CI: 1.60, 9.06)
213 times the odds of HBsAg positivity compared with having no new sexual partners in the last three
214 months. All associations held across sensitivity analyses in which definitions of household HBV exposure
215 status were varied (**Supplementary Figure 4**). We did not observe evidence that engaging in
216 transactional sex was associated with higher odds of HBsAg positivity (OR: 1.00, 95% CI: 0.53, 1.89).

217
218 Among exposed direct offspring, a one-year increase in age was associated with higher HBsAg
219 prevalence [adjusted PR = 1.42; 95% CI = (1.07, 1.89)]. Offspring older than 13 years in 2022 (born before
220 pentavalent vaccine introduction in DRC) had 13.24 (1.61, 108.63) times the HBsAg prevalence of those
221 ≤ 13 years (**Figure 3, Supplementary Figure 5**). Exposed offspring from wealthier households had 0.22
222 [95% CI: (0.06, 0.74)] times the HBsAg prevalence of those from households in the lowest wealth
223 quartile. Sharing nail clippers in the household [adjusted PR: 3.35; 95% CI: (1.12, 9.97)] and using street
224 salons [adjusted PR: 3.08; 95% CI: (1.06, 10.89)] in the community were both associated with higher
225 HBsAg prevalence among exposed direct offspring. No attributes or practices were associated with
226 HBsAg-positivity among unexposed direct offspring, but this analysis was limited by few (n=3)
227 unexposed direct offspring who were HBsAg-positive (**Supplementary Table 3**).

228
229 Exposed and unexposed other household members had too few infections (n=7 and n=5, respectively) to
230 estimate PRs within these subgroups, but among exposed other household members, history of
231 traditional scarring was associated with HBsAg-positivity (p-value = 0.002; **Supplementary Table 4**).
232 Among unexposed other household members, no attributes or practices were significantly associated
233 with HBsAg positivity (**Supplementary Table 5**).

234 235 **HBV vaccination**

236 A total of 330 HBsAg-negative household members were living with someone who was HBsAg-positive.
237 At six months following enrollment completion, 162 (49%) had initiated the vaccine series and 149 (45%)
238 had completed the series (92% completion rate); 51 (15%) had refused vaccination outright; the
239 remainder had accepted but did not present for vaccination. When we followed up with vaccine-eligible
240 participants, the most-cited reasons for non-vaccination were vaccine hesitancy and distance to the
241 maternities where we offered vaccination.

242 243 **Discussion**

244
245 In this large household HBV investigation in the DRC, we identified evidence of ongoing HBV
246 transmission and opportunities for a range of HBV prevention efforts. HBsAg prevalence was higher in
247 the households of HBsAg-positive mothers, indicating that the existing HIV PMTCT infrastructure in
248 countries like the DRC could be used to identify households for targeted prevention. Factors associated
249 with HBsAg-positivity among index mothers included increasing age, current marriage, and recent sexual
250 behavior (having at least two recent partners, having at least one new recent partner, or declining to
251 answer recent partner questions). Among exposed direct offspring, HBsAg-positivity was associated with
252 increasing age, fewer household resources, and use of shared nail clippers or street salons. We also
253 observed evidence that traditional scarring could be associated with HBsAg positivity among other
254 household members. These potential sources of HBV infection corroborate findings from past studies in

255 other African settings,^{25,31} and suggest priority behaviors or subgroups for intervention in urban Kinshasa
256 that may be relevant to other megacities in Africa.

257
258 Roll-out of infant HBV vaccination within the pentavalent series starting at six weeks of age is one
259 possible explanation for the HBV prevalence among exposed children, which was more than 13 times as
260 high for those who were >13 years compared to those who were ≤13 years in 2022. Our findings are
261 consistent with results of a study conducted in Burkina Faso, which also reported lower HBsAg positivity
262 among children born to 215 HBsAg-positive mothers after HBV vaccine rollout but before birth dose.³²
263 We observed relatively few HBsAg-positive offspring, suggestive of infrequent perinatal transmission
264 given that proven PMTCT measures have not been implemented in DRC. Our observation of incident and
265 cleared infections among mothers further suggests recent HBV exposures and that horizontal
266 transmission is occurring. Accumulation of HBV exposures in households and communities over time is a
267 plausible explanation for the observed increasing HBsAg-positivity risk with age.

268
269 The strong observed associations with sexual exposures provides further evidence of horizontal HBV
270 transmission. The strongest association with HBsAg positivity was observed for index mothers who
271 reported multiple recent or any new sexual partners or who declined to discuss. This finding is in line
272 with a past study of DRC healthcare workers that found an association between multiple sexual partners
273 and HBsAg positivity.¹⁷ We did not observe evidence that engagement in transactional sex was
274 associated with HBsAg positivity. Interestingly, we observed lower HBsAg prevalence among male
275 partners of HBsAg-positive mothers compared with HBsAg-negative mothers. While precision was
276 limited, one explanation for this finding is that sexual partners have been exposed and recovered from
277 infection, which could be clarified by serological analysis that was not feasible with DBS samples.
278 Together, our findings indicate that development of HBV prevention efforts for the broader population
279 of women of childbearing age are needed in the DRC.

280
281 Our experience in this study indicates that integration of antenatal HBsAg testing alongside existing HIV
282 testing is acceptable to maternity center staff and patients, consistent with prior findings.²¹ While rapid
283 HBsAg tests are available for just over 1 USD per test, scaling this effort is often hindered by a siloed
284 approach to healthcare in which HIV funders do not cover HBsAg or syphilis screening, both of which are
285 recommended for triple elimination.³³ Women who are HBsAg-positive could be offered HBV antiviral
286 prophylaxis and HBV birth-dose vaccine for their newborns, and given the opportunity to have
287 household members screened and vaccinated. ANC visits also provide opportunities for health
288 education. While these measures are not currently offered in the DRC, increasing evidence indicates
289 that they would be effective and feasible in the DRC.²¹

290
291 Our study has several limitations. First, our cross-sectional study design does not allow for analysis of
292 the timing of infection, preventing definitive determination of vertical vs. horizontal transmission.
293 Serological analysis and HBV sequencing could improve our characterization of these transmission
294 patterns, but serological assays for DBS samples collected in this study and often used in resource-
295 limited settings like DRC continue to perform poorly for HBV.³⁴ Second, enrollment of households
296 several months to over a year after recruitment during antenatal screening meant that we inherently
297 selected a population based in Kinshasa. Individuals with frequent time out of Kinshasa might have a
298 different prevalence of HBV infection and associated behaviors not captured in this study. Third,
299 household members absent during our enrollment visit and thus not included in the study may also be
300 infected, potentially resulting in biased prevalence estimates. However, our estimates remain useful for
301 clinicians assessing household infection risk as part of routine antenatal care and for development of
302 targeted prevention programs.

303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343

Conclusions

In the largest and most detailed household investigation of HBV in DRC conducted to-date, we found that HBV screening as part of existing HIV PMTCT programs can be used to identify infected mothers and household members, and households where vaccination may be particularly beneficial. In addition to WHO-recommended efforts to prevent mother-to-infant HBV transmission, prevention of horizontal transmission within households and communities should be prioritized. Possible interventions include education to reduce blood exposure through household item sharing and to improve protection during sexual intercourse in affected households, as well as targeted vaccination programs in adults. While additional research is needed to determine precise HBV transmission mechanisms in settings like the DRC, our findings provide a foundation for developing new HBV transmission prevention strategies.

Acknowledgements

We would like to thank all participants who offered their time and participation in this study. We would also like to thank the staff at Binza and Kingasani maternities for their collaboration in conducting antenatal HBsAg screening and administering Euvax HBV vaccination. We would also like to thank Dr. Alpha Oumar Diallo for his contributions establishing the REDCap study database. Lastly, we thank the late Dr. Steve Meshnick for his mentorship and contributions to the conceptualization of this study. Data may be made available upon reasonable request. JBP, PT, MY, and SM conceptualized the study. PN, SN, JM, MT, NM, and MMK collected data. CEM, AJNB, PN, SN, JM, NM, MMK, LJ, JBP, PT, ME, JKE, and KAP analyzed and interpreted results. CEM, AJNB, JBP, PT, ME, JKE, and KAP drafted the manuscript. All authors have reviewed and approved the manuscript.

Funding

This investigator-sponsored research study was funded by Gilead Sciences, Inc. It was partially supported by the National Institutes of Health (F30AI169752 and D43TW009340 supporting CEM; K08AI148607 to PT; R01HD087993 to MY; and UL1TR002489 to UNC NCTracs for REDCap data collection). MT, NM, and MY are partially supported by U01AI096299 and R01HD105526. CEM is also supported by the UNC Royster Graduate Fellowship.

Competing interests

Outside the submitted work: JBP and PT report non-financial support from Abbott Laboratories (donation of hepatitis B laboratory testing and reagents for other studies), and JBP reports consulting for Zymeron Corporation. The remaining authors report no competing interests.

344 **References**

- 345 1. World Health Organization. Global Progress Report on HIV, Viral Hepatitis and Sexually
346 Transmitted Infections, 2021: Accountability for the Global Health Sector Strategies 2016–
347 2021: Actions for Impact: Web Annex 1: Key Data at a Glance. World Health Organization;
348 2021. Accessed October 12, 2021. <https://apps.who.int/iris/handle/10665/342808>
- 349 2. Razavi-Shearer D, Gamkrelidze I, Nguyen MH, et al. Global prevalence, treatment, and
350 prevention of hepatitis B virus infection in 2016: a modelling study. *The Lancet*
351 *Gastroenterology & Hepatology*. 2018;3(6):383-403. doi:10.1016/S2468-1253(18)30056-6
- 352 3. Nayagam S, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B: a
353 modelling study. *The Lancet Infectious Diseases*. 2016;16(12):1399-1408.
354 doi:10.1016/S1473-3099(16)30204-3
- 355 4. McNaughton AL, Lourenço J, Bester PA, et al. Hepatitis B virus seroepidemiology data for
356 Africa: Modelling intervention strategies based on a systematic review and meta-analysis.
357 *PLOS Medicine*. 2020;17(4):e1003068. doi:10.1371/journal.pmed.1003068
- 358 5. World Health Organization. WHO releases first-ever global guidance for country validation
359 of viral hepatitis B and C elimination. Accessed July 14, 2021.
360 [https://www.who.int/news/item/25-06-2021-who-releases-first-ever-global-guidance-for-](https://www.who.int/news/item/25-06-2021-who-releases-first-ever-global-guidance-for-country-validation-of-viral-hepatitis-b-and-c-elimination)
361 [country-validation-of-viral-hepatitis-b-and-c-elimination](https://www.who.int/news/item/25-06-2021-who-releases-first-ever-global-guidance-for-country-validation-of-viral-hepatitis-b-and-c-elimination)
- 362 6. Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. *J Gastroenterol Hepatol*.
363 2013;28 Suppl 1:7-10. doi:10.1111/jgh.12220
- 364 7. Edmunds' WJ, Medley' GF, Nokes DJ, O'Callaghan CJ, Whittle HC, Hall' AJ. Epidemiological
365 patterns of hepatitis B virus (HBV) in highly endemic areas. Published online 1996:13.
- 366 8. Shan S, Cui F, Jia J. How to control highly endemic hepatitis B in Asia. *Liver Int*. 2018;38
367 Suppl 1:122-125. doi:10.1111/liv.13625
- 368 9. Dumpis U, Holmes EC, Mendy M, et al. Transmission of hepatitis B virus infection in
369 Gambian families revealed by phylogenetic analysis. *Journal of Hepatology*. 2001;35(1):99-
370 104. doi:10.1016/S0168-8278(01)00064-2
- 371 10. Kiire CF. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from
372 tropical and subtropical Africa. *Gut*. 1996;38(Suppl 2):S5-12. doi:10.1136/gut.38.Suppl_2.S5
- 373 11. Thompson P, Parr JB, Holzmayer V, et al. Seroepidemiology of Hepatitis B in the Democratic
374 Republic of the Congo. *Am J Trop Med Hyg*. 2019;101(1):226-229. doi:10.4269/ajtmh.18-
375 0883
- 376 12. Naughton B, Abramson R, Wang A, Kwan-Gett T. DRC Survey: An overview of demographics,
377 health, and financial services in the Democratic Republic of the Congo. University of

- 378 Washington Strategic Analysis, Research and Training (START) Center. Published online
379 March 29, 2017.
- 380 13. Shindano TA, Kabinda JM, Mitashi P, Horsmans Y. Hepatitis B virus infection in the
381 Democratic Republic of Congo: a systematic review of prevalence studies (2000–2016). *J*
382 *Public Health (Berl)*. 2018;26(5):595-603. doi:10.1007/s10389-018-0894-8
- 383 14. Mpody C, Thompson P, Tabala M, et al. Hepatitis B infection among pregnant and post-
384 partum women living with HIV and on antiretroviral therapy in Kinshasa, DR Congo: A cross-
385 sectional study. *PLoS One*. 2019;14(5). doi:10.1371/journal.pone.0216293
- 386 15. Mudji J, Madinga B, Horsmans Y. Seroprevalence of Viral Hepatitis B and C and Knowledge
387 of the Hepatitis B Virus among Pregnant Women Attending Prenatal Care in the Democratic
388 Republic of Congo. *Am J Trop Med Hyg*. 2021;104(3):1096-1100. doi:10.4269/ajtmh.20-
389 0804
- 390 16. Kabinda JM, Akilimali TS, Miyanga AS, Donnen P, Michèle DW. Hepatitis B, Hepatitis C and
391 HIV in Pregnant Women in the Community in the Democratic Republic of Congo. *WJA*.
392 2015;05(02):124-130. doi:10.4236/wja.2015.52015
- 393 17. Lungosi MB, Muzembo BA, Mbendi NC, et al. Assessing the prevalence of hepatitis B virus
394 infection among health care workers in a referral hospital in Kisantu, Congo DR: a pilot
395 study. *Ind Health*. 2019;57(5):621-626. doi:10.2486/indhealth.2018-0166
- 396 18. Bisimwa PB, Masemo DB, Byabene AK, et al. High Prevalence of Hepatitis B and HIV among
397 Women Survivors of Sexual Violence in South Kivu Province, Eastern Democratic Republic of
398 Congo. *Infectious Diseases (except HIV/AIDS)*; 2023. doi:10.1101/2023.09.22.23295978
- 399 19. UNICEF. UNICEF Data Warehouse, V1.15. WHO/UNICEF estimates of national immunization
400 coverage, 2021 revision: Democratic Republic of Congo, time period: 2020. Published 2021.
401 Accessed June 19, 2023. https://data.unicef.org/resources/data_explorer/unicef_f/
- 402 20. World Health Organization. Prevention of Mother-to-Child Transmission of Hepatitis B
403 Virus: Guidelines on Antiviral Prophylaxis in Pregnancy. World Health Organization; 2020.
404 Accessed November 20, 2022. <https://apps.who.int/iris/handle/10665/333391>
- 405 21. Thompson P, Morgan CE, Ngimbi P, et al. Arresting vertical transmission of hepatitis B virus
406 (AVERT-HBV) in pregnant women and their neonates in the Democratic Republic of the
407 Congo: a feasibility study. *The Lancet Global Health*. Published online August
408 2021:S2214109X21003041. doi:10.1016/S2214-109X(21)00304-1
- 409 22. Boisson A, Morgan CE, Fried B, et al. Barriers and facilitators to timely birth-dose vaccines in
410 Kinshasa Province, the DRC: a qualitative study. *Journal of Global Health Reports*.
411 2022;6:e2022028. doi:10.29392/001c.35449
- 412 23. Alere Medical Co., Ltd. Fact sheet: DETERMINE™ HBsAg 2.

- 413 24. CDC. Hepatitis B FAQs | CDC. Centers for Disease Control and Prevention. Published
414 October 27, 2020. Accessed June 14, 2021. <https://www.cdc.gov/hepatitis/hbv/bfaq.htm>
- 415 25. Martinson FEA, Weigle KA, Royce RA, Weber DJ, Suchindran CM, Lemon SM. Risk Factors for
416 Horizontal Transmission of Hepatitis B Virus in a Rural District in Ghana. *American Journal of*
417 *Epidemiology*. 1998;147(5):478-487. doi:10.1093/oxfordjournals.aje.a009474
- 418 26. Eroglu C, Zivalioglu M, Esen S, Sunbul M, Leblebicioglu H. Detection of Hepatitis B Virus in
419 Used Razor Blades by PCR. *Hepat Mon*. 2010;10(1):22-25.
- 420 27. Awili HO, Gitao GC, Muchemi GM. Seroprevalence and Risk Factors for Hepatitis B Virus
421 Infection in Adolescent Blood Donors within Selected Counties of Western Kenya. *Biomed*
422 *Res Int*. 2020;2020:8578172. doi:10.1155/2020/8578172
- 423 28. The Government of the Democratic Republic of Congo. Annual progress report 2007
424 (English). Published online April 30, 2008.
425 [https://www.gavi.org/sites/default/files/document/annual-progress-report-congo%2C-](https://www.gavi.org/sites/default/files/document/annual-progress-report-congo%2C-democratic-republic-of-the-2007pdf.pdf)
426 [democratic-republic-of-the-2007pdf.pdf](https://www.gavi.org/sites/default/files/document/annual-progress-report-congo%2C-democratic-republic-of-the-2007pdf.pdf)
- 427 29. Le gouvernement de Republique Democratique du Congo. Rapport annuel de situation
428 2008. Published online Mai 2009.
429 [https://www.gavi.org/sites/default/files/document/annual-progress-report-congo%2C-](https://www.gavi.org/sites/default/files/document/annual-progress-report-congo%2C-democratic-republic-of-the-2008--francais-pdf.pdf)
430 [democratic-republic-of-the-2008--francais-pdf.pdf](https://www.gavi.org/sites/default/files/document/annual-progress-report-congo%2C-democratic-republic-of-the-2008--francais-pdf.pdf)
- 431 30. Cummings P. The Relative Merits of Risk Ratios and Odds Ratios. *Archives of Pediatrics &*
432 *Adolescent Medicine*. 2009;163(5):438-445. doi:10.1001/archpediatrics.2009.31
- 433 31. Tazinkeng NN, Teuwafeu DG, Asombang AW, et al. Factors associated with hepatitis B and C
434 among adults in Buea, Cameroon: A community-based cross-sectional study. *Liver Int*.
435 2022;42(11):2396-2402. doi:10.1111/liv.15390
- 436 32. Guingané AN, Kaboré R, Shimakawa Y, et al. Screening for Hepatitis B in partners and
437 children of women positive for surface antigen, Burkina Faso. *Bull World Health Organ*.
438 2022;100(4):256-267. doi:10.2471/BLT.21.287015
- 439 33. Zhang L, Tao Y, Woodring J, et al. Integrated approach for triple elimination of mother-to-
440 child transmission of HIV, hepatitis B and syphilis is highly effective and cost-effective: an
441 economic evaluation. *Int J Epidemiol*. 2019;48(4):1327-1339. doi:10.1093/ije/dyz037
- 442 34. Amini F, Auma E, Hsia Y, et al. Reliability of dried blood spot (DBS) cards in antibody
443 measurement: A systematic review. *PLOS ONE*. 2021;16(3):e0248218.
444 doi:10.1371/journal.pone.0248218

445

Table 1. Characteristics of study households (A) and participants (B) enrolled in the HOVER-HBV study.

A. Households

Characteristic	Exposed households (HBsAg+ index mother)*	Unexposed households (HBsAg- index mother)*	Overall
n	100	100	200
Household members enrolled, median (IQR)	5 (3, 6)	5 (3, 7)	5 (3, 6)
Enrolled direct offspring of index mothers per household, median (IQR)	3 (1, 4)	3 (1, 4)	3 (1, 4)
Household structures			
Vertical: Index mother/direct offspring	87 (87%)	89 (89%)	176 (88%)
Sexual: index mother and male partner enrolled	52 (52%)	34 (34%)	86 (43%)
Modern housing (%) [†]	21 (21%)	20 (20%)	41 (20.5%)
Wealth quartile (%) [‡]			
Lowest	28 (28%)	22 (22%)	50 (25%)
Lower middle	20 (20%)	30 (30%)	50 (25%)
Upper middle	24 (24%)	26 (26%)	50 (25%)
Highest wealth	28 (28%)	22 (22%)	50 (25%)

B. Individuals

Characteristic	Index mothers		Direct offspring		Other household members		Overall
	Exposed	Unexposed	Exposed	Unexposed	Exposed	Unexposed	
n	100	100	228	239	156	183	1,006
HBsAg testing, n	100	100	227	237	156	183	1,003
HBsAg+ at enrollment, n (%)	96 (96.0)	2 (2.0)	12 (5.3)	3 (1.3)	7 (4.5)	5 (2.9)	125
Age, median years (IQR)	33 (29, 37)	30 (25, 37)	6 (2.6, 11)	6 (2, 11)	26 (13, 40)	22 (13.2, 38)	15 (5, 30)
Age group, years (%) [§]							
>13	100 (100.0)	100 (100.0)	41 (18.0)	38 (15.9)	121 (77.6)	145 (79.2)	545 (54.2)
≤13	0 (0.0)	0 (0.0)	187 (82.0)	201 (84.1)	35 (22.4)	38 (20.8)	461 (45.8)
Female sex, n (%)	100 (100.0)	100 (100.0)	119 (52.5)	142 (59.5)	76 (48.1)	95 (55.2)	637 (63.3)
Relationship to index mother, n (%)							
Index mother	100 (100.0)	100 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	200 (19.9)
Son/daughter	0 (0.0)	0 (0.0)	228 (100.0)	239 (100.0)	0 (0.0)	0 (0.0)	475 (46.4)
Current male partner	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	52 (33.1)	34 (18.6)	86 (8.5)
Brother/sister	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	39 (24.8)	60 (32.8)	90 (9.9)
Nephew/niece	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	41 (26.1)	53 (29.0)	93 (9.3)
Other	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25 (15.9)	36 (19.7)	61 (6.0)
Marital status, n (%)							
Married or living with someone	85 (85.0)	75 (75.0)	0 (0.0)	2 (7.4)	56 (50.0)	49 (37.4)	267 (52.8)
Never married	7 (7.0)	16 (16.0)	36 (100.0)	25 (92.6)	45 (40.2)	66 (50.4)	195 (38.5)

Divorced/widowed	8 (8.0)	9 (9.0)	0 (0.0)	0 (0.0)	11 (9.8)	16 (12.2)	44 (8.7)
Household is primary residence, n (%)	98 (98.0)	98 (98.0)	225 (98.7)	234 (98.3)	135 (86.5)	163 (89.1)	954 (94.8)
Slept in household last night, n (%)	100 (100.0)	99 (99.0)	225 (99.1)	238 (99.6)	144 (92.9)	178 (97.2)	984 (98.0)
≥1 past positive HBV test, n (%)	90 (90.0)	0 (0.0)	0 (0.0)	1 (0.4)	3 (1.9)	1 (0.5)	95 (9.4)
Past positive HIV test, n (%)	16 (16.0)	1 (1.0)	3 (1.3)	0 (0.0)	1 (0.6)	1 (0.5)	22 (2.2)
Current HAART regimen, n (%)							
Tenofovir, lamivudine, dolutegravir	15 (93.8)	1 (100.0)	1 (33.3)	0 (0.0)	1 (100.0)	1 (100.0)	19 (86.4)
Dolutegravir, abacavir	0 (0.0)	0 (0.0)	2 (66.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (9.1)
Not taking	1 (6.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.5)
Pregnant at household enrollment, n (%)	56 (56.6)	13 (13.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (4.4)	72 (20.2)

*Exposure status based on index mother's antenatal recruitment point-of-care HBsAg screening.

†Modern housing is a composite variable of materials used in the roofing, walls, flooring, and windows, using previously published categorizations further described in the Supplementary Material.

‡Wealth index is calculated by a principal components analysis accounting for household attributes further described in the Supplementary Material.

§Age in 2022 dichotomized using 13 years to approximate whether participant was born before or after infant pentavalent vaccination introduction in 2009, further described in Supplementary Material.

¶Survey question asked to those age 15 years and above.

Table 2. HBsAg prevalence among exposed and unexposed household members.

Stratification	Comparison	HBsAg+	HBsAg-	Total	Prevalence		Unadjusted prevalence ratio	95% CI	Adjusted prevalence ratio†	95% CI‡
					(%)	95% CI*				
Overall	Exposed§	19	364	383	5.0	2.8, 7.1	2.61	1.20, 6.25	2.52	0.88, 7.23
	Unexposed	8	412	420	1.9	0.6, 3.2	Ref		Ref	
Direct offspring	Exposed	12	215	227	5.3	2.4, 8.2	4.18	1.35, 18.16	3.33	0.94, 11.84
	Unexposed	3	234	237	1.3	0.0, 2.7	Ref		Ref	
Other	Exposed	7	149	156	4.5	1.2, 7.7	1.64	0.53, 5.45	1.01	0.24, 4.25
	Unexposed	5	178	183	2.7	0.4, 5.1	Ref		Ref	
Male partner#	Exposed	1	51	52	1.9	0.0, 5.7	0.65	0.04, 10.10	0.65	0.04, 10.10
	Unexposed	1	33	34	2.9	0.0, 8.6	Ref		Ref	
Exposed	Direct offspring	12	215	227	5.3	2.4, 8.2	1.17	0.49, 3.10	1.25	0.48, 3.24
	Other	7	149	156	4.5	1.2, 7.7	Ref		Ref	
Unexposed	Direct offspring	3	234	237	1.3	0.0, 2.7	0.46	0.10, 1.86	0.91	0.26, 3.17
	Other	5	178	183	2.7	0.4, 5.1	Ref		Ref	

* Prevalence confidence interval calculated using $Z_{crit}=1.96$ and the formula: $\hat{p} \pm z_{critical} * \sqrt{\frac{\hat{p}(1-\hat{p})}{n}}$


†Adjusted for household clustering using a random intercept term for household in `glmer()` from `lme4` package in R4.1.1.

‡ Wald confidence intervals from multilevel model.

§Primary exposure status defined by index mother HBsAg status at antenatal recruitment. See supplementary Material for sensitivity analyses for alternate definitions of HBsAg positivity of index mothers.

#Male partners are included in the “other” category elsewhere in the analysis, but are separated here for the purpose of examining sexual relationships.

Figure 1. Recruitment and enrollment of households of HBsAg-positive and HBsAg-negative index mothers.




*Prior screening occurred before the HOVER study; total number of women screened not available.


It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Figure 2. Enrolled households by geography and household structure.

A. Locations of enrolled households by exposure status ($n_{hh} = 200$)



B. Household networks by participant HBsAg status ($n_{ind} = 1,006$)



C. Categorization of households by patterns of HBsAg positivity among enrolled individuals*



* Categories are mutually exclusive.

[†] In four exposed households, index mothers recovered from infection (HBsAg-positive at antenatal recruitment and were HBsAg-negative at household enrollment).


[‡] In both households, the index mother had an incident infection between recruitment and enrollment (HBsAg-negative to HBsAg-positive).

Figure 3. Attributes and practices associated with HBsAg-positivity among index mothers (A) and exposed direct offspring (B).

A. Index mothers

	OR (95% CI)*
Age (1-year increase)	1.06 (1.01, 1.11)
Marriage: Never vs married	0.39 (0.14, 0.96)
Marriage: Divorced/widowed vs married	0.78 (0.28, 2.15)
Upper wealth quartiles (Q4-Q2) vs lowest (Q1)	0.73 (0.38, 1.38)
Shares toothbrushes in household	1.00 (0.39, 2.55)
Shares razors in household	0.67 (0.37, 1.20)
Shares nail clippers in household	0.62 (0.35, 1.08)
Premasticates food for someone else	0.53 (0.16, 1.60)
≥1 past transfusion vs none	1.99 (0.78, 5.50)
Uses street salons	1.65 (0.89, 3.11)
Manicures/pedicures outside home	1.74 (0.91, 3.41)
Tattoos	0.48 (0.12, 1.58)
Traditional scarring	1.00 (0.35, 2.83)
Has engaged in transactional sex or refused to answer vs no	1.00 (0.53, 1.89)
Age of sexual debut: <18 yrs vs ≥18 yrs	1.21 (0.66, 2.23)
Age of sexual debut: Refused/don't know vs ≥18 yrs	4.53 (1.54, 16.63)
Sexual partners in last 3 months: ≥2 or refused vs ≤1	4.41 (1.35, 19.82)
New sexual partners in last 3 months: ≥1 or refuse vs none new	3.63 (1.60, 9.06)
Sexual partners in last 12 months: ≥2 or refused vs ≤1	6.68 (1.76, 43.7)
New sexual partners in last 12 months: ≥1 or refuse vs none new	3.32 (1.39, 8.84)


*Unadjusted odds ratio



B. Exposed direct offspring

	PR (95% CI)*
Born before HBV vaccination†	13.24 (1.61, 108.63)
1-year increase in age†	1.42 (1.07, 1.89)
Female sex	0.43 (0.14, 1.31)
Upper wealth quartiles (Q4-Q2) vs lowest (Q1)	0.22 (0.06, 0.74)
Shares razors in household	0.97 (0.25, 3.68)
Shares nail clippers in household	3.35 (1.12, 9.97)
≥1 past transfusion vs none	0.58 (0.08, 4.49)
Uses street salons	3.08 (1.06, 8.95)
Manicures outside home	2.54 (0.59, 10.89)
Sexual partners in last 3 months: ≥2 or refused vs ≤1	1.02 (0.15, 6.75)

*Prevalence ratio adjusted for household clustering.
 †Logistic-binomial approximation of log(PR) due to rare outcome.



Index mothers' HBsAg result from recruitment screening used for index mothers and exposure status of direct offspring. Supplementary Material IV shows sensitivity analyses using other definitions of HBsAg positivity and exposure. Unadjusted OR shown as measure of association for index mothers due to case-control recruitment of mothers. PR adjusted for household clustering shown for direct offspring.